Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Active-comparator Controlled and a Long-term Clinical Trial to Study the Safety of MK-0954A (L100/H12.5 mg) in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®]

NCT01307033 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT01307033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01307033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Active-comparator Controlled and a Long-term Clinical Trial to Study the Safety of MK-0954A (L100/H12.5 mg) in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®]
Lead sponsor
Organon and Co
Phase
Phase 3
Overall status
Completed
Start date
March 29, 2011
Completion date
December 4, 2012
Enrollment
278 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension